Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.
FDA could find itself in danger of losing budget authority if it does not meet the goals in its user fee agreements, threatening a potentially deeper funding cut than the administration already has proposed.
Sen. Richard Burr, R-NC, has floated the idea of adding a provision to the user fee legislation that would dock...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
